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Summary
 
This report investigates the response of CD8
 
1
 
 T cells to antigens presented by B cells. When
C57BL/6 mice were injected with syngeneic B cells coated with the K
 
b
 
-restricted ovalbumin
(OVA) determinant OVA
 
257–264
 
, OVA-specific cytotoxic T lymphocyte (CTL) tolerance was
observed. To investigate the mechanism of tolerance induction, in vitro–activated CD8
 
1
 
 
 
T
cells from the K
 
b
 
-restricted, OVA-specific T cell receptor transgenic line OT-I (OT-I cells)
were cultured for 15 h with antigen-bearing B cells, and their survival was determined. Anti-
gen recognition led to the killing of the B cells and, surprisingly, to the death of a large propor-
tion of the OT-I CTLs. T cell death involved Fas (CD95), since OT-I cells deficient in CD95
molecules showed preferential survival after recognition of antigen on B cells. To investigate
the tolerance mechanism in vivo, naive OT-I T cells were adoptively transferred into normal
mice, and these mice were coinjected with antigen-bearing B cells. In this case, OT-I cells pro-
liferated transiently and were then lost from the secondary lymphoid compartment. These data
provide the first demonstration that B cells can directly tolerize CD8
 
1
 
 T cells, and suggest that
this occurs via CD95-mediated, activation-induced deletion.
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B
 
cells express relatively high levels of class I MHC
molecules and therefore potentially play a role as
APCs for CD8
 
1
 
 T cells. In vitro evidence suggests that B
cells can stimulate IL-2 production and CTL activity by ei-
ther primed CD8
 
1
 
 T cell clones or hybridomas (1–3).
However, studies in B cell–deficient mice suggest that B
cells are not required as APCs during the inductive phase of
naive CD8
 
1
 
 T cell responses (4). In fact, it has been re-
ported that B cells fail to induce naive CD8
 
1
 
 T cells to
generate primary CTL activity in vitro (5) and can induce
secondary in vitro unresponsiveness in CD8
 
1
 
 T cell clones
(6). In adult mice, B cells have been shown to induce in
vivo CTL tolerance to the minor antigen H-Y (7), but
whether this was due to direct tolerance of the CD8
 
1
 
 T
cell compartment was not addressed. CTL responses to
H-Y are known to be CD4
 
1
 
 T cell dependent (8, 9), and
there is a great deal of evidence that B cell presentation of
antigen to mature CD4
 
1
 
 T cells is tolerogenic (10–16).
Thus, it was unclear whether H-Y–specific CTL tolerance
was due to the direct tolerance of CD8
 
1
 
 T cells, or oc-
curred because H-Y–specific CD4
 
1
 
 helper T cells were
tolerized. In this latter case, the CTLs themselves might
have been completely unaffected by antigen-bearing B
cells, but failed to be primed in the absence of CD4
 
1
 
 T cell
help. In this report, we demonstrate that CD8
 
1
 
 T cells can
be directly tolerized after encounter with antigen on B
cells. The basis of this tolerance is examined.
 
Materials and Methods
 
Mice.
 
Mice were bred and maintained at the Walter and Eliza
Hall Institute for Medical Research. OT-I mice have been de-
scribed previously (17), and were maintained on the recombina-
tion-activating gene (RAG)
 
1
 
-1–deficient C57BL/6 (B6) back-
ground. Some experiments used OT-I mice expressing the 
 
lpr
 
mutation (OT-I.lpr) or back-crossed to bm1; both of these strains
were RAG-1 sufficient. For all experiments, mice between 8 and
16 wk of age were used.
 
B Cell Purification.
 
B cells were purified as described previ-
ously (16). In brief, spleen cells were depleted of red blood cells,
 
1
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 B6, C57BL/6; HEM, Hepes Eagle’s Me-
dium; RAG, recombination-activating gene.
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and passed over a 30–35-ml Sephadex G-10 column (Amersham
Pharmacia Biotech, Uppsala, Sweden) to remove adherent cells.
T cells were then removed by treatment with a mixture of anti-
Thy1.2 (J1j), anti-CD8 (3.168), and anti-CD4 (RL172) antibody
supernatants at 4
 
8
 
C for 30 min, followed by two successive treat-
ments with rabbit C (C-Six Diagnostics Inc., Mequon, WI) at
37
 
8
 
C for 20 min. After passage over a second Sephadex G-10 col-
umn, the cells were analyzed by flow cytometry using anti-B220–
FITC and found to be 
 
.
 
95% B220
 
1
 
. To separate small, resting B
cells, the B cell suspension was centrifuged at 3,000 rpm for 30
min over a discontinuous Percoll (Amersham Pharmacia Biotech)
density gradient containing 
 
r
 
 
 
5 
 
1.05–1.09 layers as described
previously (16). Cells from the 
 
r
 
 
 
5 
 
1.07–1.08 interface were used
as resting B cells. B cells were coated at 5 
 
3 
 
10
 
7
 
/ml with 0, 0.1,
1.0, or 10 
 
m
 
g/ml OVA
 
257–264 
 
peptide in Hepes Eagle’s Medium
(HEM) containing 2.5% FCS for 60 min at 37
 
8
 
C and washed
three times before counting. Mice were immunized intravenously
with 10–15 
 
3 
 
10
 
6
 
 B cells in HEM.
 
Dendritic Cell Generation.
 
Bone marrow–derived dendritic cells
were prepared as described previously (18) with the following
modifications. In brief, bone marrow cells from B6 mice were
cultured in 94-mm tissue culture dishes (Greiner Labortechnik,
Frickenhausen, Germany) at a density of 5 
 
3 
 
10
 
5
 
/ml in complete
DMEM with 10% FCS as well as 5% supernatant of X63-Ag8
myeloma cells transfected with murine GM-CSF (provided by
Dr. David Gray, Hammersmith Hospital, London, UK). On day 3,
nonadherent granulocytes were removed and the media replaced.
Loosely adherent cells were harvested on day 6 and recultured
overnight in fresh GM-CSF–containing media. Nonadherent den-
dritic cells were harvested the next day and used for immunization.
 
CTL Challenge.
 
1 wk after immunization with B cells, B6
mice were challenged with an intravenous injection of 20–25 
 
3
 
10
 
6
 
 irradiated spleen cells loaded intracytoplasmically with OVA
by osmotic shock, or with a subcutaneous injection of 10–20 
 
m
 
g
OVA
 
257–264
 
 in CFA as described previously (19).
 
In Vitro Generation of OVA-specific CTLs.
 
CTLs were gener-
ated as described previously (19). LU/spleen were calculated as
the total number of CTL effectors present after the 6 d of in vitro
stimulation, divided by the number of effectors required to give
20% OVA-specific lysis (1 LU).
 
In Vitro Cultures of OVA-presenting B Cells with Activated OT-I
Cells.
 
Activated OVA-specific CD8
 
1
 
 T cells were generated
using LN cells from OT-I mice on (
 
a
 
) a B6 RAG-1–deficient
background, (
 
b
 
) an 
 
lpr
 
 background, or (
 
c
 
) from OT-I.bm1 bone
marrow into B6 chimeras. Cells were cultured at 2.5
 
 3 
 
10
 
5
 
 cells/
ml for 6 d in 30 ml RPMI containing 10% FCS, 50 
 
m
 
M 2-ME, 2
mM 
 
l
 
-glutamine, and 2.5 
 
3 
 
10
 
6
 
 cells/ml irradiated syngeneic
spleen cells coated with OVA
 
257–264
 
 at 0.1 
 
m
 
g/ml. On day 3, cul-
tures were diluted twofold with RPMI containing 10% FCS, 50
 
m
 
M 2-ME, 2 mM 
 
l
 
-glutamine, and 20 U/ml rIL-2. To remove
any contaminating B cells or CD4
 
1
 
 T cells, 6 d–activated OT-I
cells were exposed to a mixture containing anti-HSA (J11d) and
anti-CD4 (RL172) mAb supernatants for 30 min at 4
 
8
 
C and then
treated with rabbit C for 20 min at 37
 
8
 
C. Cells were washed
three times in HEM with 2.5% FCS and filtered through nylon
mesh, and in some experiments, activated OT-I cells were puri-
fied further by passage over nylon wool. Finally, 5 
 
3 
 
10
 
5
 
 acti-
vated OT-I cells were cultured together with a total of 5 
 
3 
 
10
 
5
 
cells consisting of a 1:1 mixture of B6 to bm1 B cells in 200 
 
m
 
l
RPMI containing 10% FCS, 50 
 
m
 
M 2-ME, and 2 mM 
 
l
 
-glu-
tamine. Before in vitro culture, the mixture of B6 plus bm1 B
cells was coated with OVA
 
257–264
 
 at 0.1 
 
m
 
g/ml or left uncoated.
Up to six replicate cultures were set up for each T cell–B cell
combination. 15 h later, the cells from each well were recovered
and analyzed by flow cytometry using anti-B220–FITC (6B2)
and anti-K
 
b
 
 (5-F-1)–biotin followed by Streptavidin-PE (Caltag
Laboratories, Inc., San Francisco, CA).
 
Adoptive Transfer Experiments.
 
OT-I T cells were prepared as
described previously (20). 4–7 
 
3 
 
10
 
6
 
 OT-I cells were injected in-
travenously into (B6 
 
3 
 
B6.Kathy)F
 
1
 
 host mice 1 d before immu-
nization with 10–15 
 
3 
 
10
 
6
 
 B cells. The LNs and spleen of each
mouse were analyzed by flow cytometry on day 3, 7, or 14 after
the initial B cell immunization using anti-Thy1.1–FITC (OX-7;
PharMingen, San Diego, CA), anti-CD8–PE (CT-CD8a; Caltag
Laboratories, Inc.), and anti-V
 
a
 
2 (B20.1)–biotin followed by
Streptavidin–Tri-color (Caltag Laboratories, Inc.). The number
of OT-I cells was determined for each organ by multiplying the
cell number by the percentage of Thy1.1
 
2
 
CD8
 
1
 
V
 
a
 
2
 
1
 
 cells. For
individual litters, the background number of Thy1.1
 
2
 
CD8
 
1
 
V
 
a
 
2
 
1
 
cells of a control littermate that did not receive an injection
of OT-I cells was subtracted from the number of CD8
 
1
 
Thy1.1
 
2
 
V
 
a
 
2
 
1
 
 cells found in the same organ of each test host
mouse. To measure the CTL function of adoptively transferred
OT-I cells, 5, 2.5, 1.25, 0.63, 0.31, or 0.16 
 
3 
 
10
 
5
 
 LN cells from
the (B6 
 
3 
 
B6.Kathy)F
 
1
 
 host mice were cultured in triplicate with
5 
 
3 
 
10
 
5
 
 irradiated, OVA-loaded spleen cells in 200 
 
m
 
l RPMI
containing 10% FCS, 50 
 
m
 
M 2-ME, and 2mM 
 
l
 
-glutamine. The
number of OT-I responders per well was calculated by multiply-
ing the number of LN cells by the percentage of Thy1.12
CD81Va21 cells as determined by flow cytometry. After 5 d, the
cytotoxicity of each well was assessed on 104  51Cr-labeled EL4
cells alone or EL4 cells coated with 1 mg/ml OVA257–264 during
51Cr labeling as described (19).
Results
B Cell Presentation of Antigen Causes Direct Tolerization of
CD81 T Cells. Presentation of antigen by B cells has
been shown to cause CTL tolerance for the male-specific
anti–H-Y response (7). However, this response is depen-
dent on CD41 T cell help (8, 9), raising the possibility that
CTL tolerance occurred indirectly by the induction of
CD41 T cell tolerance. To investigate whether antigen-
bearing B cells can induce tolerance by directly affecting
the CD81 T cell population, B cells coated with the Kb-
restricted OVA peptide OVA257–264 were tested for their
ability to tolerize OVA-specific CTL responses generated
by intravenous injection of irradiated spleen cells loaded in-
tracytoplasmically with OVA protein (OVA-loaded spleen
cells [21]). Injection of B6 mice with 107 OVA257–264-
coated B cells reduced the subsequent OVA-specific CTL
response upon challenge with OVA-loaded spleen cells
(Fig. 1 a). On average, the ability to generate OVA-specific
CTLs was diminished 10-fold, but many mice showed
.100-fold weaker responses (Fig. 1 c). Tolerance induction
by B cells was long-lasting, as thymectomized mice in-
jected with OVA257–264-coated B cells were unable to gen-
erate OVA-specific CTLs 12 wk after immunization (data
not shown). The level of antigen expression also affected
tolerance induction, which was slightly more efficient
when B cells were coated with a higher concentration (10
vs. 1 mg/ml) of peptide (Fig. 1 c). Although CD41 T cell
tolerance induction by B cells has been shown to be more1979 Bennett et al.
effective using resting B cells (11, 12), we found that for
CD81 T cells, small resting B cells were no more tolero-
genic than unfractionated B cells (Fig. 1 c). Under similar
conditions, peptide-pulsed dendritic cells were not tolero-
genic, but instead primed hosts for stronger responses to
OVA-loaded spleen cell challenge (data not shown).
We have found that the priming protocol used to mea-
sure CD81 T cell tolerance induction by B cells, i.e.,
OVA-loaded spleen cell challenge, is CD41 T cell depen-
dent (19). Therefore, it was possible (though unlikely given
that tolerization only involved the class I–restricted deter-
minant) that CTL tolerance in this model may have also
occurred indirectly through the induction of CD41 T cell
tolerance. To determine whether tolerance resulted from a
direct effect on CD81 T cells, we examined B cell toler-
ance induction under conditions where CTL generation
was not CD41 T cell dependent, i.e., by priming sub-
cutaneously with OVA257–264 in CFA (19). OVA257–264-
coated B cell–primed mice challenged subcutaneously with
OVA257–264 in CFA also failed to generate OVA-specific
CTLs (Fig. 1 b), confirming that the CD81 T cells were di-
rectly tolerized.
Activated CD81 T Cells Die after Recognizing Antigen on B
Cells In Vitro. To investigate the mechanism of CTL tol-
erance induction by antigen-bearing B cells, we examined
the in vitro response of activated CD81 T cells to antigen-
bearing B cells. For these experiments, in vitro–activated
CD81 T cells from the OVA-specific TCR transgenic line
OT-I were used. These mice are of a B6 genotype. OT-I
cells plus syngeneic B6 B cells (unpulsed or pulsed with
OVA257–264) were cultured together for 15 h and then ana-
lyzed by flow cytometry to determine the survival of each
cell population relative to an internal control population of
bm1 B cells. These latter cells bear the Kbm1 MHC mole-
cule and therefore cannot present OVA257–264 to OT-I cells
(20). The survival of the OT-I cells (B2202, Kb1) and B6 B
cells (B2201, Kb1) was then examined relative to the bm1
control B cells (B2201, Kb2) (Fig. 2, a and b). As expected,
the activated OT-I cells killed a large proportion of B6 B
cells, as seen by the reduction in B6 B cells relative to bm1
B cells in the presence of antigen. Surprisingly, there was
also a dramatic loss of OT-I cells relative to the bm1 B cell
control population. Six separate experiments revealed a
consistent loss of the CD81 CTLs during their 15-h culture
with antigen-bearing B6 B cells. This result was the same
whether the bm1 B cells were cocultured as described
above, or whether they were simply added at the end of
the culture period, just before flow cytometric analysis. In
an example of the latter experiment, there were 2.1 3 105
OT-I cells and 1.7 3 105 B6 B cells present after 15 h of
Figure 1. OVA257–264-coated B cells induce OVA-specific CTL tolerance
in B6 mice. B6 mice were injected intravenously with 107 OVA257–264-
coated B6 B cells, unpulsed B6 B cells, or medium alone, and rechal-
lenged 7 d later with (a and c) 25 3 106 OVA-loaded spleen cells injected
intravenously or (b) 10 mg OVA257–264 in CFA injected subcutaneously.
After an additional 7 d, their spleens were removed and stimulated in
vitro for 6 d before a 4-h chromium release assay was performed. (a and b)
Percent specific lysis of 51Cr-labeled OVA257–264-coated EL4 (filled sym-
bols) and EL4 (open symbols) in mice injected with B cells coated with
OVA257–264 at 10 mg/ml (squares) or with medium alone (circles). (c) The
number of OVA-specific LU/spleen for individual mice (filled triangles)
treated as in a,  and calculated as described in Materials and Methods.
OVAp, OVA257–264 coated. Open circles, average LU/spleen for each group.
Figure 2. Activated OT-I cells kill peptide-coated B cells, but are
themselves killed by a CD95-dependent mechanism during this recogni-
tion process. 5 3 105 previously stimulated (a and b) OT-I cells or (c and
d) OT-I.lpr cells were cultured for 15 h with 5 3 105 B6 plus bm1 B cells
coated without (a and c) or with (b and d) 0.1 mg/ml OVA257–264 peptide.
The wells were then analyzed by flow cytometry using anti-B220–FITC
and anti-Kb (5-F-1)–biotin followed by Streptavidin-PE.1980 B Cells Directly Tolerize CD8+ T Cells
culture in the absence of peptide. When the B6 B cells
were first coated with peptide, only 0.31 3 105 OT-I cells
and 0.83 3 105 B6 B cells remained. This represents an
85% loss of OT-I cells and a 51% loss of B6 B cells.
The antigen-specific loss of OT-I cells was not due to
fratricide as a result of re-presentation of OVA peptide by
CTLs to each other, since OT-I cells bearing the nonpre-
senting Kbm1 molecule, instead of Kb, were also killed (data
not shown). To investigate whether Fas (CD95)-mediated
signaling (for a review, see reference 22) was involved in
the death of activated CD81 T cells, the OT-I mice were
crossed to lpr mice, which express a genetic defect in CD95
(23). When activated OT-I.lpr cells were cultured for 15 h
with antigen-bearing B cells, survival was greatly improved
(Fig. 2, c and d). This suggested that activated cells were
killed by a CD95-dependent mechanism. Unlike activated
OT-I cells, naive OT-I cells did not kill antigen-bearing B
cells and were not killed during this 15-h culture period
(data not shown).
Expansion and Loss of Naive OT-I T Cells in Response to
Antigen-bearing B Cells In Vivo. As shown earlier, CTL tol-
erance induction in B6 mice involved recognition of anti-
gen on B cells by naive CD81 T cells. To further charac-
terize this response in vivo, naive OT-I cells were injected
into Thy1 congenic (B6 3 B6.Kathy)F1 mice. After injec-
tion of OVA257–264-coated B cells, the fate of the adoptively
transferred OT-I cells was followed by flow cytometry.
The number of OT-I cells recovered from the LNs and
spleen of individual mice was then calculated as a percent-
age of the number of OT-I cells in unprimed control mice
(Fig. 3). Exposure to antigen-bearing B cells resulted in a
large expansion of OT-I cells by day 3, as seen by an in-
crease in the relative number of OT-I cells in primed ver-
sus untreated controls (Fig. 3 a), and, in separate experi-
ments, by the observed proliferation of carboxyfluorescein
succinimidyl ester–labeled OT-I cells under similar condi-
tions (data not shown). The extent of OT-I cell expansion
was similar to that induced by OVA-loaded spleen cells
(Fig. 3 a), which are known to induce strong OVA-specific
CTL responses (21). However, by day 7 most of the OT-I
cells generated in response to OVA257–264-coated B cells
had disappeared (Fig. 3 b), and the number of OT-I cells
remained similar to or below that of unprimed mice to day
14 (Fig. 3 c). In contrast, mice immunized with OVA-
loaded spleen cells showed further expansion of OT-I cells
up to day 14. The OT-I cells remaining in B cell–treated
mice were not anergic, as they were able to lyse OVA-
expressing targets as efficiently as naive OT-I cells, after 5 d
restimulation in vitro (Fig. 4). Therefore, although an im-
munogenic form of OVA (OVA-loaded spleen cells) was
able to induce sustained proliferation of OT-I cells, toler-
ance induction by B cells was characterized by proliferation
and then rapid deletion of OVA-specific CD81 T cells.
To test whether the incomplete deletion of OT-I cells
was the result of insufficient antigen exposure, OT-I cell
survival was examined after two injections of B cells, 5 d
apart. Under these circumstances, deletion of OT-I cells
was slightly more efficient (Fig. 3 c).
Discussion
Most studies examining tolerance induction by B cells
have focussed on the response of CD41 T cells (10–16).
This report represents the first demonstration that naive
CD81 T cells can be directly tolerized by recognition of
antigen on B cells. One other study has addressed the role
of B cells as tolerogenic APCs in vivo for CD81 T cell re-
sponses by showing that injection of male B cells into fe-
male mice resulted in H-Y–specific CTL tolerance (7).
However, generation of H-Y–specific CTLs has been re-
ported to require CD41 T cell help (8, 9). Thus, failure to
induce H-Y–specific CTLs might have simply reflected
tolerant CD41 T helper cells. We showed that OVA-spe-
Figure 3. Naive OT-I cells rapidly expand and disappear in response to
antigen-bearing B cells in vivo. Naive OT-I cells were adoptively trans-
ferred into (B6 3 B6.Kathy)F1 hosts 1 d before intravenous immunization
with medium alone (unprimed), 107 OVA257–264-coated B cells (OVAp-
coated B), or 25 3 106 OVA-loaded spleen cells (OL spleen). Mice given
two injections of OVA257–264-coated B cells received their second injec-
tion 5 d after the first. On day 3 (a), 7 (b), and 14 (c) after the first immu-
nization, the total number of OT-I cells in the spleen and LNs of individ-
ual mice was determined using flow cytometry and expressed as a
percentage of the total number of OT-I cells from one or more unprimed
control animals in each experiment (filled triangles). Open circles, average
percentage of OT-I cells relative to unprimed controls for each group.
Figure 4. OT-I cells remain-
ing at day 14 in B cell–treated
mice possess full CTL effector
function. 14 d after immuniza-
tion with OVA257–264-coated B
cells (squares) or medium alone
(circles), the LN cells from adop-
tively transferred (B6 3 B6.
Kathy)F1 host mice were titrated
into 200 ml microcultures and
stimulated for 5 d with irradiated
OVA-loaded spleen cells. The
number of responder OT-I cells
per well was determined by flow
cytometry. The cytotoxicity was then measured in a 4-h chromium re-
lease assay using 51Cr-labeled OVA257–264-coated EL4 (filled symbols) and
uncoated EL4 (open symbols) targets. This experiment was performed four
times with two to four mice per group.1981 Bennett et al.
cific CTLs were directly tolerized by OVA257–264-coated B
cells, since mice primed with OVA257–264 peptide–coated B
cells responded weakly to both OVA-loaded spleen cells
(Fig. 1, a and c) and OVA peptide in CFA (Fig. 1 b). This
latter response is CD41 T cell independent, indicating that
CTLs exposed to B cells bearing class I–restricted determi-
nants are directly tolerized.
Since CTL tolerance has been reported to be the default
response when CD4 help is unavailable (24, 25), it is possi-
ble that B cells induced CTL tolerance simply because they
failed to provide determinants for stimulation of CD41 T
cell help. Even if class II–restricted determinants had been
available, naive CD41 T cells are reported to be tolerized
by recognition of antigen on B cells, which should also lead
to a lack of help and, consequently, CTL tolerance. It re-
mains to be addressed whether provision of primed CD41
T cell help, which cannot be tolerized by B cells, will allow
B cells to stimulate naive CTL responses.
Our in vitro studies showed that peptide-coated B cells
could be lysed by activated OT-I cells, confirming that
CD81 T cells could recognize antigen on B cells (Fig. 2).
More importantly, however, these experiments revealed
that activated, but not naive, OT-I cells died shortly after
interacting with antigen-bearing B cells. The loss of acti-
vated OT-I cells after recognition of antigen on B cells
suggested that the pathway to B cell–mediated tolerance
induction may require the interaction of activated CD81 T
cells with B cells. Protection of activated OT-I.lpr CD81 T
cells from death implied that CD95-mediated signaling
played an important role in this death pathway.
A great deal of evidence suggests that CD95-mediated
signaling is the predominant mediator of CD41 T cell
death in vitro via a mechanism termed activation-induced
cell death (AICD [26–30]). This is mediated through the
interaction of CD95 with its ligand (CD95L [31, 32]), ex-
pressed on the same (26, 27) or neighboring (33, 34) anti-
gen-activated T cells, and occurs within 24 h for previously
activated cells (35). Although there is some evidence that
CD95 is involved in the death of activated CD81 T cells
(33, 36, 37), TNFR/TNF-mediated apoptosis has also
been suggested to be important (35, 38, 39). This latter
mechanism takes 40–48 h to induce apoptosis of activated
T cells (35). Our observation that up to 85% of activated
CD81 T cells were killed within 15 h argues against a role
for TNFR signaling for B cell–induced deletion of CD81
T cells. The fact that activated CD81 T cells expressing the
mutant CD95 gene were largely protected from deletion
suggests that CD95/CD95L interactions are more impor-
tant in this case.
It was at first surprising that naive OT-I cells, in contrast
to activated OT-I cells, were not killed when cultured for
15 h in vitro with antigen-bearing B cells. Interestingly,
cultures containing naive OT-I cells showed extensive pro-
liferation on day 2 (data not shown). This is consistent with
the idea that to be deleted, OT-I cells must first be acti-
vated and, as a consequence, may proliferate before being
killed. However, the combined effects of proliferation, nu-
trient utilization, and activation-induced cell death in vitro
made it very difficult to analyze the response of naive OT-I
cells under these conditions; therefore, we concentrated
our efforts on examining the response of naive OT-I cells
in vivo.
Deletional tolerance after antigen-specific activation in
vivo has been reported for both CD41 and CD81 T cells
responding to a variety of antigens. These include conven-
tional peptide or protein antigens (40–42), superantigens
(43–47), minor antigens (48), viral antigens (49, 50), and
tissue-specific antigens (51–53). These studies were charac-
terized by an early, transient period of antigen-specific T
cell proliferation followed by rapid deletion of most re-
sponding T cells. OT-I cells displayed similar response ki-
netics upon exposure to peptide-coated B cells in vivo (Fig.
3). At day 3, there was marked proliferation of OT-I cells,
but by day 7 the number of OT-I cells had declined to be-
low prestimulation levels, where it remained. Altogether,
our data suggest that B cells tolerize CD81 T cells via acti-
vation of naive cells followed by CD95-mediated deletion
of their activated progeny.
Interestingly, not all OT-I cells were deleted in response
to OVA-bearing B cells. Unlike other models where those
T cells that remain become hyporesponsive to further anti-
gen challenge (40, 41, 44, 48, 52), the OT-I cells that were
not deleted showed full CTL function (Fig. 4). Given that
deletion is reported to be antigen dose dependent (42, 43),
these cells may represent OT-I cells that were inadequately
stimulated by the tolerogenic B cells. Perhaps all of the B
cells were killed before all activated CD81 T cells could re-
encounter antigen for induction of CD95-mediated death.
We attempted to address this issue by introducing a second
dose of OVA-coated B cells 5 d after the first immuniza-
tion, but this only slightly enhanced OT-I deletion at day
14. However, in TCR transgenic models, changes to the
extent and nature of tolerance induction may require very
large variations in antigen dose due to the relatively high
number of responsive T cells (52, 54).
It is important to note that we have not addressed
whether B cells are unique in their ability to induce dele-
tion of CD81 T cells. It may be that any cell type lacking
the appropriate accessory signals will cause such deletion.
The aim of this report was to specifically examine the effect
of antigen presentation by B cells to CD81 T cells. To this
end, we have shown that B cells are directly tolerogenic for
CD81 T cells. This tolerance appears to be preceded by ac-
tivation and proliferation of antigen-specific CD81 T cells.
Once activated, CD81 T cells appear to be susceptible to
CD95-mediated killing by reencounter with antigen on B
cells, at least in vitro. Taken together, our data suggest that
B cell presentation of antigen to CD81 T cells leads to acti-
vation followed by deletion of the antigen-specific popula-
tion.1982 B Cells Directly Tolerize CD8+ T Cells
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